InhibitoryKIR2DL2Gene: Risk for Deep Endometriosis in Euro-descendants

Carregando...
Imagem de Miniatura
Citações na Scopus
9
Tipo de produção
article
Data de publicação
2021
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER HEIDELBERG
Citação
REPRODUCTIVE SCIENCES, v.28, n.1, p.291-304, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Endometriosis (EDT) is an inflammatory disease characterized by implantation/growth of endometrial tissue, glands, and/or stroma, outside the uterus. Reduced NK cell cytotoxic activity has been implicated in its pathogenesis, together with other immunologic alterations. We investigated the influence ofKIRgene polymorphisms and their HLA ligand combinations in deep endometriosis (DE) susceptibility. One hundred sixty women with a histological diagnosis of DE and 202 control women without the disease, who underwent laparoscopy, were enrolled. The DE group was subdivided into initial (I/II;n = 60) and advanced stages (III/IV,n = 100).KIRand HLA class I gene polymorphisms were typed by PCR-SSP and sequence-based-typing (SBT), respectively. We observed a significant association ofKIR2DL2, an inhibitory gene of B haplotype, conferring risk for DE in Euro-descendants. Positive associations of Bx haplotype and centromeric AB segments were also found. However, no association with KIR-HLA ligand combination was observed. Our data suggestKIR2DL2gene to be a relevant factor favoring NK inhibition in DE in Euro-descendants, contributing to the defective NK cytotoxic activity and impaired clearance of ectopic endometrial cells in the disease.
Palavras-chave
Endometriosis, NK cells, Killer cell immunoglobulin-like receptors, KIR-HLA ligand combinations
Referências
  1. Armstrong RA, 2014, OPHTHAL PHYSL OPT, V34, P502, DOI 10.1111/opo.12131
  2. ARUMUGAM K, 1992, AUST NZ J OBSTET GYN, V32, P164, DOI 10.1111/j.1479-828X.1992.tb01932.x
  3. Augusto DG, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00121
  4. Burney RO, 2012, FERTIL STERIL, V98, P511, DOI 10.1016/j.fertnstert.2012.06.029
  5. Canis M, 1997, FERTIL STERIL, V67, P817
  6. Charron D, 1996, HUM IMMUNOL, V47, P1, DOI 10.1016/S0198-8859(96)85602-3
  7. Chou YC, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61702-y
  8. COLONNA M, 1993, P NATL ACAD SCI USA, V90, P12000, DOI 10.1073/pnas.90.24.12000
  9. Cooley S, 2010, BLOOD, V116, P2411, DOI 10.1182/blood-2010-05-283051
  10. CORNILLIE FJ, 1990, FERTIL STERIL, V53, P978
  11. Excoffier L, 2005, EVOL BIOINFORM, V1, P47, DOI 10.1177/117693430500100003
  12. Fauconnier A, 2005, HUM REPROD UPDATE, V11, P595, DOI 10.1093/humupd/dmi029
  13. Faure M, 2002, J IMMUNOL, V168, P6208, DOI 10.4049/jimmunol.168.12.6208
  14. Feyaerts D, 2018, HUM REPROD, V33, P441, DOI 10.1093/humrep/dey001
  15. GARZETTI GG, 1993, OBSTET GYNECOL, V81, P665
  16. Giudice LC, 2004, LANCET, V364, P1789, DOI 10.1016/S0140-6736(04)17403-5
  17. Gonzalez-Foruria I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119961
  18. Hiby SE, 2004, J EXP MED, V200, P957, DOI 10.1084/jem.20041214
  19. Hiby SE, 2014, J IMMUNOL, V192, P5069, DOI 10.4049/jimmunol.1400577
  20. HO HN, 1995, HUM REPROD, V10, P2671, DOI 10.1093/oxfordjournals.humrep.a135765
  21. Hsu KC, 2002, J IMMUNOL, V169, P5118, DOI 10.4049/jimmunol.169.9.5118
  22. Ivarsson MA, 2017, MUCOSAL IMMUNOL, V10, P322, DOI 10.1038/mi.2016.50
  23. Jh M, 2014, HDB BIOL STAT
  24. Jonsson AH, 2010, J IMMUNOL, V184, P3424, DOI 10.4049/jimmunol.0904057
  25. KIRSHON B, 1989, J REPROD MED, V34, P215
  26. Kitawaki J, 2007, AM J REPROD IMMUNOL, V58, P481, DOI 10.1111/j.1600-0897.2007.00533.x
  27. Lavender KJ, 2007, J IMMUNOL, V179, P6856, DOI 10.4049/jimmunol.179.10.6856
  28. LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S
  29. Lowe DP, 2009, RHEUMATOLOGY, V48, P359, DOI 10.1093/rheumatology/ken503
  30. Marsh SGE, 2003, TISSUE ANTIGENS, V62, P79, DOI 10.1034/j.1399-0039.2003.00072.x
  31. Martin MP, 2002, NAT GENET, V31, P429, DOI 10.1038/ng934
  32. Matalliotakis IM, 2008, ARCH GYNECOL OBSTET, V277, P389, DOI 10.1007/s00404-007-0479-1
  33. Middleton D, 2010, IMMUNOLOGY, V129, P8, DOI 10.1111/j.1365-2567.2009.03208.x
  34. Missmer SA, 2004, AM J EPIDEMIOL, V160, P784, DOI 10.1093/aje/kwh275
  35. Moesta AK, 2008, J IMMUNOL, V180, P3969, DOI 10.4049/jimmunol.180.6.3969
  36. Moesta AK, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00336
  37. Montaldo E, 2013, CYTOM PART A, V83A, P702, DOI 10.1002/cyto.a.22302
  38. Naumova E, 2005, CANCER IMMUNOL IMMUN, V54, P172, DOI 10.1007/s00262-004-0575-z
  39. Nisolle M, 1997, FERTIL STERIL, V68, P585, DOI 10.1016/S0015-0282(97)00191-X
  40. Nowak I, 2015, IMMUNOGENETICS, V67, P203, DOI 10.1007/s00251-015-0828-3
  41. OOSTERLYNCK DJ, 1991, FERTIL STERIL, V56, P45
  42. OOSTERLYNCK DJ, 1992, FERTIL STERIL, V58, P290
  43. Parra FC, 2003, P NATL ACAD SCI USA, V100, P177, DOI 10.1073/pnas.0126614100
  44. Pyo CW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015115
  45. Rached MR, 2019, EUR J OBSTET GYN R B, V235, P36, DOI 10.1016/j.ejogrb.2019.01.030
  46. Ranstam J, 2016, OSTEOARTHR CARTILAGE, V24, P763, DOI 10.1016/j.joca.2016.01.008
  47. Sullivan KM, 2009, PUBLIC HEALTH REP, V124, P471, DOI 10.1177/003335490912400320
  48. Suzuki Y, 2004, J INVEST DERMATOL, V122, P1133, DOI 10.1111/j.0022-202X.2004.22517.x
  49. Uhrberg M, 1997, IMMUNITY, V7, P753, DOI 10.1016/S1074-7613(00)80394-5
  50. Valiante NM, 1997, IMMUNITY, V7, P739, DOI 10.1016/S1074-7613(00)80393-3
  51. Verheyden S, 2004, LEUKEMIA, V18, P2002, DOI 10.1038/sj.leu.2403525
  52. Vilches C, 2002, ANNU REV IMMUNOL, V20, P217, DOI 10.1146/annurev.immunol.20.092501.134942
  53. Winter CC, 1997, J IMMUNOL, V158, P4026
  54. Winter CC, 1998, J IMMUNOL, V161, P571